DHX35

Summary

DHX35 (DEAH-box helicase 35, HGNC:15861) is a protein-coding gene on chromosome 20q11.23-q12, encoding Probable ATP-dependent RNA helicase DHX35 (Q9H5Z1). May be involved in pre-mRNA splicing. It is a selective cancer dependency (DepMap: 20.2% of cell lines).

DEAD box proteins characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of the DEAD box protein family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. The function of this gene product which is a member of this family, has not been determined. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 60625 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 117 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 20.2% of screened cell lines
• MANE Select transcript: NM_021931

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15861
Approved symbol	DHX35
Name	DEAH-box helicase 35
Location	20q11.23-q12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ22759, KAIA0875
Ensembl gene	ENSG00000101452
Ensembl biotype	protein_coding
Entrez	60625

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 9 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000252011, ENST00000373323, ENST00000373325, ENST00000449559, ENST00000482619, ENST00000484417, ENST00000493450, ENST00000652169, ENST00000863972, ENST00000933117, ENST00000954514, ENST00000954515, ENST00000954516

RefSeq mRNA: 2 — MANE Select: NM_021931 NM_001190809, NM_021931

CCDS: CCDS13310, CCDS54463

Canonical transcript exons

ENST00000252011 — 22 exons

Exon	Start	End
ENSE00001597395	38969081	38969214
ENSE00001693109	38988813	38988917
ENSE00001726243	38983699	38983776
ENSE00001755842	38972559	38972651
ENSE00002216121	38962344	38962407
ENSE00003464773	38991454	38991515
ENSE00003481824	39023690	39023767
ENSE00003488722	39002772	39002868
ENSE00003491294	39030704	39030775
ENSE00003508169	39014880	39014934
ENSE00003519254	39028418	39028499
ENSE00003524438	38992356	38992425
ENSE00003529822	39038499	39039721
ENSE00003556859	39001730	39001842
ENSE00003597254	39006146	39006356
ENSE00003622546	39003749	39003907
ENSE00003624910	38994821	38994880
ENSE00003635227	39010280	39010404
ENSE00003641686	39018804	39018899
ENSE00003653664	39034206	39034317
ENSE00003675063	39025230	39025359
ENSE00003677128	39021841	39021935

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 90.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.0363 / max 149.6492, expressed in 1768 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
184597	10.0363	1768

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus muscularis layer	UBERON:0035833	90.45	gold quality
lower esophagus	UBERON:0013473	90.42	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.37	gold quality
mucosa of stomach	UBERON:0001199	88.37	gold quality
muscle layer of sigmoid colon	UBERON:0035805	88.35	gold quality
lower esophagus mucosa	UBERON:0035834	88.22	gold quality
body of uterus	UBERON:0009853	86.15	gold quality
apex of heart	UBERON:0002098	85.99	gold quality
right coronary artery	UBERON:0001625	85.95	gold quality
esophagus	UBERON:0001043	85.73	gold quality
tibial artery	UBERON:0007610	85.68	gold quality
popliteal artery	UBERON:0002250	85.67	gold quality
right atrium auricular region	UBERON:0006631	84.85	gold quality
aorta	UBERON:0000947	84.77	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.71	gold quality
left coronary artery	UBERON:0001626	84.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.18	gold quality
mucosa of transverse colon	UBERON:0004991	84.14	gold quality
ascending aorta	UBERON:0001496	84.03	gold quality
thoracic aorta	UBERON:0001515	83.96	gold quality
transverse colon	UBERON:0001157	83.87	gold quality
coronary artery	UBERON:0001621	82.98	gold quality
endocervix	UBERON:0000458	82.93	gold quality
rectum	UBERON:0001052	82.89	gold quality
ectocervix	UBERON:0012249	82.80	gold quality
descending thoracic aorta	UBERON:0002345	82.79	gold quality
cardiac atrium	UBERON:0002081	82.77	gold quality
left ovary	UBERON:0002119	82.68	gold quality
left uterine tube	UBERON:0001303	82.46	gold quality
right ovary	UBERON:0002118	82.32	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

64 targeting DHX35, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-4487	99.96	64.58	1252
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-498-5P	99.76	69.64	1807
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-548M	99.70	68.87	1749
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-548V	99.29	69.47	1157
HSA-MIR-3692-5P	99.29	67.04	1421
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-10524-5P	99.05	66.08	963

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 20.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• human DDX40gene, a new member of the DEAH-box protein family shares 53% and 43% amino acid identity with human DDX8 and yeast Drh1.DDX40 may play roles in pre-mRNA splicing, ribosome biogenesis and other RNA processing functions (PMID:12522690)
• DRH1 - a novel blood-based HPV tumour marker. (PMID:32535546)
• The RNA helicase DHX35 functions as a co-sensor for RIG-I-mediated innate immunity. (PMID:39037956)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	dhx35	ENSDARG00000063419
mus_musculus	Dhx35	ENSMUSG00000027655
rattus_norvegicus	Dhx35	ENSRNOG00000015928
drosophila_melanogaster	CG3225	FBGN0031631
caenorhabditis_elegans		WBGENE00022056
caenorhabditis_elegans		WBGENE00022433

Paralogs (18): DHX33 (ENSG00000005100), YTHDC2 (ENSG00000047188), DHX29 (ENSG00000067248), DHX8 (ENSG00000067596), DHX32 (ENSG00000089876), DHX40 (ENSG00000108406), DHX15 (ENSG00000109606), HELB (ENSG00000127311), DHX30 (ENSG00000132153), DHX34 (ENSG00000134815), DHX9 (ENSG00000135829), DHX38 (ENSG00000140829), DQX1 (ENSG00000144045), DHX37 (ENSG00000150990), TDRD9 (ENSG00000156414), DHX57 (ENSG00000163214), DHX36 (ENSG00000174953), DHX16 (ENSG00000204560)

Protein

Protein identifiers

Probable ATP-dependent RNA helicase DHX35 — Q9H5Z1 (reviewed: Q9H5Z1)

Alternative names: DEAH box protein 35

All UniProt accessions (4): Q9H5Z1, F2Z2Z2, Q5THQ7, Q5THR1

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in pre-mRNA splicing.

Subunit / interactions. Identified in the spliceosome C complex.

Similarity. Belongs to the DEAD box helicase family. DEAH subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H5Z1-1	1	yes
Q9H5Z1-2	2

RefSeq proteins (2): NP_001177738, NP_068750* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001650	Helicase_C-like	Domain
IPR002464	DNA/RNA_helicase_DEAH_CS	Conserved_site
IPR007502	Helicase-assoc_dom	Domain
IPR011709	DEAD-box_helicase_OB_fold	Domain
IPR014001	Helicase_ATP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR048333	HA2_WH	Domain

Pfam: PF00271, PF04408, PF07717, PF21010

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (10 total): domain 2, sequence variant 2, sequence conflict 2, chain 1, short sequence motif 1, binding site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H5Z1-F1	86.94	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 77–84

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-72163	mRNA Splicing - Major Pathway

MSigDB gene sets: 112 (showing top): RNGTGGGC_UNKNOWN, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, TGACCTY_ERR1_Q2, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_DN, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, REACTOME_PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA, USF_01, GOBP_RNA_SPLICING, REACTOME_MRNA_SPLICING, USF_02, GOBP_EMBRYO_DEVELOPMENT, chr20q11, ACEVEDO_LIVER_CANCER_UP, REACTOME_METABOLISM_OF_RNA

GO Biological Process (4): mRNA splicing, via spliceosome (GO:0000398), in utero embryonic development (GO:0001701), mRNA processing (GO:0006397), RNA splicing (GO:0008380)

GO Molecular Function (7): RNA binding (GO:0003723), RNA helicase activity (GO:0003724), helicase activity (GO:0004386), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), hydrolase activity (GO:0016787)

GO Cellular Component (3): nucleoplasm (GO:0005654), catalytic step 2 spliceosome (GO:0071013), spliceosomal complex (GO:0005681)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
mRNA Splicing	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	2
ATP-dependent activity	2
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile	1
mRNA processing	1
chordate embryonic development	1
mRNA metabolic process	1
nucleic acid binding	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
catalytic activity	1
nuclear lumen	1
cellular anatomical structure	1
Prp19 complex	1
spliceosomal complex	1
U5 snRNP	1
catalytic complex	1
nuclear protein-containing complex	1
ribonucleoprotein complex	1

Protein interactions and networks

STRING

2752 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DHX35	ZNF676	Q8N7Q3	667
DHX35	TBC1D31	Q96DN5	625
DHX35	ZNF208	O43345	575
DHX35	ACYP2	P14621	571
DHX35	PXK	Q7Z7A4	529
DHX35	DDX23	Q9BUQ8	522
DHX35	CTC1	Q2NKJ3	521
DHX35	DDX49	Q9Y6V7	508
DHX35	SMIM23	A6NLE4	505
DHX35	STN1	Q9H668	479
DHX35	DDX55	Q8NHQ9	477
DHX35	RAB5IF	Q9BUV8	476
DHX35	SNRNP200	O75643	462
DHX35	ITCH	Q96J02	443
DHX35	ZHX3	Q9H4I2	437
DHX35	GGT7	Q9UJ14	437

IntAct

97 interactions, top by confidence:

A	B	Type	Score
SNRPF	GEMIN2	psi-mi:“MI:0914”(association)	0.910
PPIE	AQR	psi-mi:“MI:0914”(association)	0.810
PRPF19	AQR	psi-mi:“MI:0914”(association)	0.790
SNRPE	GEMIN2	psi-mi:“MI:0914”(association)	0.770
ISY1	AQR	psi-mi:“MI:0914”(association)	0.740
SYF2	AQR	psi-mi:“MI:0914”(association)	0.730
SNRPG	GEMIN2	psi-mi:“MI:0914”(association)	0.710
SNRPB	PRMT5	psi-mi:“MI:0914”(association)	0.670
SNW1	AQR	psi-mi:“MI:0914”(association)	0.650
NEUROG3	GXYLT2	psi-mi:“MI:0914”(association)	0.640
SNRPE	PRMT5	psi-mi:“MI:0914”(association)	0.530
SNRPN	PRMT5	psi-mi:“MI:0914”(association)	0.530
PRPF19	STRN	psi-mi:“MI:0914”(association)	0.530
ZC3H18	AQR	psi-mi:“MI:0914”(association)	0.530
KIAA1143	AQR	psi-mi:“MI:0914”(association)	0.530
EAPP	SNRNP200	psi-mi:“MI:0914”(association)	0.530
SNRPE	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
SNRPF	SNRPGP15	psi-mi:“MI:0914”(association)	0.530
WDR83	SH2B2	psi-mi:“MI:0914”(association)	0.530
EFTUD2	AQR	psi-mi:“MI:0914”(association)	0.530
PLRG1	AQR	psi-mi:“MI:0914”(association)	0.530

BioGRID (106): DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Proximity Label-MS), DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS), DHX35 (Affinity Capture-MS)

ESM2 similar proteins: A0A0L0P6P7, A4I2L4, A5PKR8, A8D8P8, A9U328, A9VB27, A9ZSZ2, D3TQJ5, F4IE66, F4ISQ7, O22899, O43143, O54747, O60126, O61660, O70157, O76922, O95985, O96651, P13099, P54358, P90829, P97283, Q07803, Q08BB1, Q0J0S6, Q13472, Q20875, Q22307, Q23223, Q4P1V1, Q5R9V1, Q5RAZ4, Q5RBD4, Q5XQC7, Q7K3M5, Q80VY9, Q8K0D5, Q8T2T7, Q96RP9

Diamond homologs: A1Z9L3, A2A4P0, B4GEU5, B4JT42, B4K5R2, B4RC48, D4A2Z8, F4HYJ7, F4IE66, F4IJV4, F4ILR7, F4IM84, F4JMJ3, F4JRJ6, F4K2E9, F4KGU4, O17438, O22243, O22899, O35286, O42643, O42945, O43143, O45244, O46072, O51767, O60114, O60231, O70133, O94536, P0C7L7, P0CE10, P15938, P20095, P24384, P34305, P34498, P36009, P37024, P43329

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 89 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Metabolism of non-coding RNA	6	68.0×	8e-09
mRNA Splicing - Minor Pathway	8	32.0×	6e-09
mRNA Splicing	14	27.4×	7e-15
snRNP Assembly	7	26.4×	2e-07
SARS-CoV-2 modulates host translation machinery	6	24.0×	4e-06
RNA Polymerase II Transcription Termination	6	23.5×	4e-06
Processing of Capped Intron-Containing Pre-mRNA	14	20.5×	2e-13
mRNA Splicing - Major Pathway	21	20.5×	3e-20

GO biological processes:

GO term	Partners	Fold	FDR
spliceosomal snRNP assembly	8	62.8×	8e-11
U2-type prespliceosome assembly	5	42.2×	1e-05
mRNA splicing, via spliceosome	20	24.8×	3e-20
RNA splicing	10	11.9×	1e-06
intracellular protein localization	6	8.5×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	87
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4166 predictions. Top by Δscore:

Variant	Effect	Δscore
20:38969076:TGCAG:T	acceptor_loss	1.0000
20:38969077:GCAGG:G	acceptor_loss	1.0000
20:38969078:CA:C	acceptor_loss	1.0000
20:38969080:GGT:G	acceptor_loss	1.0000
20:38969213:AGG:A	donor_loss	1.0000
20:38969215:G:GC	donor_loss	1.0000
20:38969216:T:A	donor_loss	1.0000
20:38970725:T:TA	donor_gain	1.0000
20:38970726:A:AA	donor_gain	1.0000
20:38983697:A:AG	acceptor_gain	1.0000
20:38983698:G:GA	acceptor_gain	1.0000
20:38983777:G:GG	donor_gain	1.0000
20:38988791:AGCAT:A	acceptor_gain	1.0000
20:38988792:GCATG:G	acceptor_gain	1.0000
20:38988915:AAGG:A	donor_loss	1.0000
20:38988918:G:GA	donor_loss	1.0000
20:38988919:T:G	donor_loss	1.0000
20:38992353:TA:T	acceptor_loss	1.0000
20:38992354:A:AG	acceptor_gain	1.0000
20:38992355:G:GA	acceptor_gain	1.0000
20:38992355:GT:G	acceptor_gain	1.0000
20:38992355:GTGT:G	acceptor_gain	1.0000
20:38992355:GTGTC:G	acceptor_gain	1.0000
20:38992426:G:GA	donor_loss	1.0000
20:38994878:GAC:G	donor_gain	1.0000
20:38994881:G:GG	donor_gain	1.0000
20:39002770:A:AG	acceptor_gain	1.0000
20:39002771:G:GA	acceptor_gain	1.0000
20:39002771:GT:G	acceptor_gain	1.0000
20:39002771:GTC:G	acceptor_gain	1.0000

AlphaMissense

4584 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:39010358:T:C	L434P	1.000
20:38972628:G:T	G82W	0.999
20:38972629:G:A	G82E	0.999
20:38972629:G:T	G82V	0.999
20:38972634:A:C	S84R	0.999
20:38972636:C:A	S84R	0.999
20:38972636:C:G	S84R	0.999
20:38983766:C:A	A112D	0.999
20:38988828:G:C	A121P	0.999
20:38988865:G:A	G133D	0.999
20:38988879:T:C	F138L	0.999
20:38988881:T:A	F138L	0.999
20:38988881:T:G	F138L	0.999
20:38991461:C:T	T153I	0.999
20:38992370:A:C	D176A	0.999
20:38992370:A:T	D176V	0.999
20:38992373:A:T	E177V	0.999
20:38992399:G:C	D186H	0.999
20:39002854:T:C	F280L	0.999
20:39002856:T:A	F280L	0.999
20:39002856:T:G	F280L	0.999
20:39006155:G:C	A341P	0.999
20:39006168:C:A	A345E	0.999
20:39006293:G:C	A387P	0.999
20:39006301:G:C	Q389H	0.999
20:39006301:G:T	Q389H	0.999
20:39010328:G:C	R424P	0.999
20:39010367:T:C	L437P	0.999
20:39021880:C:A	A513D	0.999
20:39023723:G:C	G543R	0.999

dbSNP variants (sampled 300 via entrez): RS1000097166 (20:39008064 C>T), RS1000182806 (20:38999133 C>T), RS1000265905 (20:38967010 A>G), RS1000267686 (20:39013480 C>T), RS1000279986 (20:38969450 A>G), RS1000290239 (20:38996019 T>C), RS1000290941 (20:39000600 G>A), RS1000326551 (20:38960855 G>A), RS1000344405 (20:39025967 A>G), RS1000358035 (20:38978343 T>G), RS1000387028 (20:39002448 T>A), RS1000466546 (20:38963086 C>A,G,T), RS1000538339 (20:38962240 T>C), RS1000543249 (20:39010086 T>C), RS1000615645 (20:38968424 C>A,T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST001024_4	Telomere length	3.000000e-07
GCST001066_2	Dialysis-related mortality	5.000000e-07
GCST001942_4	Prostate cancer	4.000000e-08
GCST003989_11	Chin dimples	2.000000e-22
GCST003999_17	Nose size	7.000000e-08
GCST004691_5	Huntington’s disease progression	2.000000e-06
GCST004862_13	Itch intensity from mosquito bite adjusted by bite size	9.000000e-06
GCST006035_6	Breast cancer and/or colorectal cancer	6.000000e-06
GCST006035_9	Breast cancer and/or colorectal cancer	9.000000e-06
GCST006110_8	Nose morphology	2.000000e-09
GCST008870_54	Keratinocyte cancer (MTAG)	6.000000e-06
GCST008871_3	Basal cell carcinoma	3.000000e-08
GCST009391_1086	Metabolite levels	2.000000e-06
GCST009391_2037	Metabolite levels	4.000000e-06
GCST012490_240	Femur bone mineral density x serum urate levels interaction	8.000000e-10
GCST90011899_56	Aspartate aminotransferase levels	1.000000e-08
GCST90011900_8	Serum alkaline phosphatase levels	2.000000e-19

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0008336	disease progression measurement
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0010176	keratinocyte carcinoma
EFO:0010543	uridine diphosphate galactose measurement
EFO:0010544	uridine diphosphate glucose measurement
EFO:0004531	urate measurement
EFO:0004736	aspartate aminotransferase measurement
EFO:0004533	alkaline phosphatase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465358 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.91	Kd	124	nM	MOLIBRESIB
6.80	IC50	160	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179185: Binding affinity against DHX35 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.1240	uM

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, decreases expression	2
Valproic Acid	decreases methylation, decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Zoledronic Acid	increases expression	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Vehicle Emissions	increases expression, increases abundance	1
Cadmium	decreases expression, decreases reaction	1
Doxorubicin	decreases expression	1
Lead	affects expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Methapyrilene	increases methylation	1
Plant Extracts	affects cotreatment, increases expression	1
Selenium	decreases expression, decreases reaction	1
Tobacco Smoke Pollution	decreases expression	1
Okadaic Acid	decreases expression	1
Lactic Acid	increases expression	1
Vitamin K 3	affects expression	1
Particulate Matter	increases abundance, increases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5391278	Binding	Inhibition of N-terminal thioredoxin-tagged human recombinant DHX35 transformed in Escherichia coli BL21(DE3)pLysS cells	Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.